LEADERSHIP R & D CLINICAL DEVELOPMENT PATIENTS INVESTORS NEWSROOM CAREERS CONTACT US HOME
News Archive
 
BioMimetic Therapeutics News Archive
Please click on any item below to read a story from our press release archive.
To see the latest news on BioMimetic Therapeutics, visit our Investor Information News Page .


BioMimetic Therapeutics Announces No Changes Requested by Independent Data Monitoring Committee to Pivotal Trial Design for Augment™ Bone Graft; 268 of 396 Patients Enrolled to Date in U.S. Pivotal Trial
Sep. 23, 2008
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the UBS Global Life Sciences Conference
Sep. 22, 2008
 
BioMimetic Therapeutics Reports 2008 Second Quarter Results; Positive Results Achieved with Augment™ Injectable Bone Graft to Enhance Healing in Foot and Ankle Fusions
Aug. 12, 2008
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Canaccord Adams Global Growth Conference
Aug. 8, 2008
 
BioMimetic Therapeutics to Report 2008 Second Quarter Financial Results on August 11; Company to Release Results of Augment Injectable Bone Graft in Foot and Ankle Fusions
Aug. 6, 2008
 
BioMimetic Therapeutics Launches Augment™ as the New Brand Name for the Company's Orthopedic Product Line; Clinical Investigator to Present Canadian Trial Results at AOFAS Meeting
June 19, 2008
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Jefferies 2nd Annual Healthcare Conference
June 20, 2008
 
BioMimetic Therapeutics Announces Highlights from Annual Meeting of Stockholders
June 12, 2008
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Bank of America Securities 2008 Healthcare Conference
May 13, 2008
 
BioMimetic Therapeutics Releases First Quarter Earnings Results; $33.4 Million Cash Received from the Sale of Orofacial Therapeutic Business
May 8, 2008
 
BioMimetic Therapeutics to Report 2008 First Quarter Financial Results on May 8
May 7, 2008
 
BioMimetic Therapeutics Receives Written Communication from FDA Confirming Status of Ongoing Pivotal Trial for GEM OS1; No Changes Recommended to Trial Design
March 27, 2008
 
BioMimetic Therapeutics Addresses FDA Communication on Regranex Safety Review
March 27, 2008
 
BioMimetic Therapeutics Reports 2007 Fourth Quarter and Year-end Results; Year Marked by Strong Cash Position, Positive Orthopedic Data and Progressing Clinical Trials
March 12, 2008
 
BioMimetic Therapeutics, Inc. Provides Updates on Clinical and Preclinical Activities; Company Receives Go Ahead from Health Canada to File GEM OS1 DLA
March 7, 2008
 
BioMimetic Therapeutics, Inc. to Highlight Clinical and Preclinical Activities at ORS and AAOS Meetings
Feb. 29, 2008
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Deutsche Bank Small and Mid Cap Growth Conference
Feb. 14, 2008
 
BioMimetic Therapeutics, Inc. to Present at BIO CEO and Investor Conference
Feb. 14, 2008
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Wachovia Healthcare Research Conference
Jan. 29, 2008
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Stanford Group Company Annual Healthcare Conference
Jan. 15, 2008
 
BioMimetic Therapeutics Closes on Transaction to Sell Remaining Dental Business
Jan. 7, 2008
 
BioMimetic Therapeutics to Sell Remaining Dental Business for Additional $40 Million Cash plus Continuation of Royalties; Company to Focus on Orthopedics, Spine and Sports Medicine
Dec. 17, 2007
 
BioMimetic Therapeutics Reports Positive Clinical Results for GEM OS®1 in Canadian Foot and Ankle Fusion Study; Clinical Success Rate of 90% Achieved in a High Risk Patient Population
Dec. 13, 2007
 
BioMimetic Therapeutics to Provide Results for GEM OS®1 Canadian Foot and Ankle Fusion Study; Company to host Conference Call on December 13 to Discuss Study Findings
Dec. 12, 2007
 
BioMimetic Therapeutics Reports 2007 Third Quarter Results
Nov. 13, 2007
 
BioMimetic Therapeutics to Report 2007 Third Quarter Financial Results on November 13
Nov. 8, 2007
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Nov. 5, 2007
 
BioMimetic Therapeutics' Study to Receive Award for Outstanding Publication from American Academy of Periodontology
Oct. 30, 2007
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at BIO InvestorForum 2007
Oct. 5, 2007
 
BioMimetic Therapeutics Reports 2007 Second Quarter Results
Aug. 14, 2007
 
BioMimetic Therapeutics to Report 2007 Second Quarter Financial Results on August 14
Aug. 9, 2007
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Canaccord Adams' 27th Annual Global Growth Conference
Aug. 7, 2007
 
BioMimetic Therapeutics' Clinical Investigator Presents
Positive Interim Data on U.S. and Canadian Foot and Ankle Clinical Trials

July 13, 2007
 
BioMimetic Therapeutics' Clinical Investigator to Present Update of Orthopedic Clinical Results from U.S. and Canadian Trials; Company to host Conference Call on July 13 to Discuss Study Findings
July 10, 2007
 
BioMimetic Therapeutics Announces Highlights from Inaugural Annual Meeting of Stockholders
June 21, 2007
 
BioMimetic Therapeutics Initiates Enrollment in E.U. Registration Trial for GEM OS®1 Bone Graft; U.S. GEM OS1 Pivotal Study Protocol Amended to Allow Shorter Follow-Up Time and More Patients
June 7, 2007
 
BioMimetic Therapeutics Reports 2007 First Quarter Results; Company Added to NASDAQ Biotechnology Index
May 14, 2007
 
BioMimetic Therapeutics to Report 2007 First Quarter Financial Results on May 14
May 11, 2007
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Deutsche Bank 32nd Annual Health Care Conference
May 1, 2007
 
BioMimetic Therapeutics Reports 2006 Fourth Quarter and Year-end Results; Company Receives Clearance to Initiate Enrollment in GEM OS1 US Pivotal Trial
March 28, 2007
 
BioMimetic Therapeutics to Report 2006 Year End Financial Results on March 28
March 22, 2007
 
BioMimetic Therapeutics Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteonecrosis of the Jaw
Feb. 21, 2007
 
BioMimetic Therapeutics, Inc. Completes Public Offering of Approximately 3.25 Million Shares of Common Stock Including the Sale of All Over-Allotment Shares
Feb. 14, 2007
 
BioMimetic Therapeutics, Inc. Announces Pricing of Public Offering
Feb. 12, 2007
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Upcoming Conferences
Feb. 9, 2007
 
BioMimetic Therapeutics Reports Positive Clinical Results
Using GEM OS®1 to Treat Distal Radius Fractures

Jan. 25, 2007
 
BioMimetic Therapeutics Announces Positive Results;
GEM OS1 Stimulates Bone Healing Comparable to Autograft

Dec. 13, 2006
 
BioMimetic Therapeutics to Announce Interim U.S. Clinical Trial Results for GEM OS1;
Press Release and Conference Call Scheduled for Dec. 13

Dec. 12, 2006
 
BioMimetic Therapeutics Reports Third Quarter 2006 Results
Nov. 6, 2006
 
BioMimetic Therapeutics' Clinical Investigator Highlights Results
of Orthopedic Clinical Trial in Canada

Nov. 6, 2006
 
BioMimetic Therapeutics' Clinical Investigator to Present Orthopedic Clinical Results
from Canadian Trial on November 4; Company to Report Third Quarter Financial Results

Nov. 2, 2006
 
BioMimetic Therapeutics Receives FDA Approval that Expands Manufacturing Capacity
for GEM 21S® ; Approval of rhPDGF-BB Manufacturing Facility

Oct. 13, 2006
 
BioMimetic Therapeutics Adds Key Talent to Board of Directors
Sep. 27, 2006
 
BioMimetic Therapeutics' Clinical Investigator Provides Results Demonstrating
Long-Term Efficacy for GEM 21S Treatment; Data Shows Continued Benefits
in Bone Growth for up to 2 Years after Treatement

Sep. 18, 2006
 
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities
at the AG Edwards Emerging Growth Conference

Sep. 15, 2006
 
BioMimetic Therapeutics' Clinical Investigators to Receive Award
from American Academy of Periodontology for Outstanding Publication;
Clinical Investigators to Present Data at Annual AAP Meeting

Sep. 14, 2006
 
BioMimetic Therapeutics Reports Second Quarter 2006 Results;
Orthopedic Clinical Trial Progress Highlights 2006 Second Quarter

Aug. 9, 2006
 
BioMimetic Therapeutics Posts Webcast re: Second Quarter 2006 Financial Results
Aug. 9, 2006
 
BioMimetic Therapeutics Successfully Completes Enrollment in Three Orthopedic
Pilot Clinical Trials for GEM OS1™ Bone Graft; Canadian Study Expanded to 60 Patients

July 11, 2006
 
BioMimetic Therapeutics to Highlight Corporate Activities
at Pacific Growth Equities Life Science Growth Conference

June 8, 2006
 
BioMimetic Therapeutics Receives Approval to Market
GEM 21S® Growth-factor Enhanced Matrix in Canada

June 7, 2006
 
Dr. Samuel E. Lynch Presides Over the NASDAQ Closing Bell to Celebrate
the Initial Public Offering of BioMimetic Therapeutics, Inc. [BMTI]

March 20, 2006
 
BioMimetic Therapeutics, Inc. Announces Pricing of Initial Public Offering
May 12, 2006
 
BioMimetic Therapeutics Initiates Clinical Trials with Novel
Bio-Active Drug-device Combination Bone Graft in Two Orthopedic Indications

March 20, 2006
 
BioMimetic Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Feb. 10, 2006
 
BioMimetic Therapeutics Announces FDA Approval of GEM 21S®
Growth-factor Enhanced Matrix for the Treatment of Periodontally-related Bone Defects

Nov. 21, 2005
 
BioMimetic Therapeutics Appoints Larry W. Papasan and James G. Murphy to its Board of Directors
Oct. 12, 2005
 
BioMimetic Pharmaceuticals Strengthens Senior Leadership Team
July 13, 2005
 
BioMimetic Pharmaceuticals, Inc. Closes Series B Venture Funding
May 21, 2005
 
BioMimetic Pharmaceuticals Raises Additional $11.8 Million in Equity Financing
May 18, 2005
 
BioMimetic Pharmaceuticals Raises $25.7 Million in Series C Financing
Nov. 4, 2004
 
BioMimetic Pharmaceuticals' Receives Approvable Recommendation from FDA Advisory Panel for GEM 21S®
July 15, 2004
 
BioMimetic Pharmaceuticals Announces Additions to Senior Management Team
Feb. 12, 2004
 
BioMimetic Pharmaceuticals and Luitpold Pharmaceuticals Establish Strategic Alliance
Jan. 8, 2003
 
Orthovita and BioMimetic Enter into a Supply Agreement
Aug. 21, 2002
 
BioMimetic Pharmaceuticals, Inc. receives investment from Novo A/S
June 25, 2001
 
BioMimetic Pharmaceuticals, Inc. Raises $6.5 Million in Venture Funding
May 17, 2001
 
BioMimetic Pharmaceuticals, Inc. Signs Agreements with Harvard Medical School and ZymoGenetics
June 5, 2001
 


BioMimetic Therapeutics, Inc. For more information, please e-mail us.
Website development and managed hosting by Acuity Marketing Communications, Inc.